The Care Ledger

The market Humana priced its 2027 Medicare Advantage plans for margin as costs rise 8% to 9%

Search
Tuesday, November 17, 2026Today's Paper From the publisher Free hospital price search Published bysoro
The Care Ledger

The market

Humana priced its 2027 Medicare Advantage plans for margin as costs rise 8% to 9%

Humana told investors on Friday that profit margin came first in its 2027 Medicare Advantage bids, with medical costs expected to rise faster than this year and drug costs faster still.

A tall red-brick office building with HUMANA across the top, seen from a street corner
A Humana office tower in Louisville, Ky., where the insurer is based. Photo: Angry Aspie, via Wikimedia Commons (CC BY 3.0)

Humana expects its core medical costs to grow 8% to 9% in 2027, up from the 7% to 8% it planned for this year, and it priced its 2027 Medicare Advantage plans with margin as the first priority, chief financial officer Celeste Mellet said on the company's third-quarter earnings call on Friday. The insurer also raised its 2026 adjusted earnings guidance to at least $9.50 a share from at least $9.00, according to the results it filed1 with the Securities and Exchange Commission (SEC).

Medicare Advantage insurers set each year's premiums, benefits and out-of-pocket limits in bids filed with the federal government the previous June, so the call was a look at the thinking behind plans that people over 65 are choosing right now. Open enrollment for 2027 coverage runs through December 7, according to Medicare5. When an insurer prices for margin against higher expected costs, there is less room in the bid for extra benefits or lower premiums. Humana did not detail benefit changes on the call. Chief executive Jim Rechtin described the 2027 lineup as protecting the benefits seniors say matter most.

What the quarter showed

Revenue reached $41.2 billion in the third quarter, up from $32.6 billion a year earlier, according to the SEC filing. Humana reported earnings of $1.33 a share on a GAAP basis and an adjusted loss of $0.70 a share. The insurance segment spent 93.7% of premiums on medical care, better than the "slightly above 94%" the company had guided to. Analysts had expected 94.39%, Reuters reported4.

Costs this year are running at the lower end of the 7% to 8% range the company had expected, Mellet said. In prepared remarks2 filed alongside the results, Humana said it expects the insurance segment's benefit ratio to rise to just above 95.5% in the fourth quarter, and that its adjusted earnings for 2026 will still be below 2025 because of a Star Ratings headwind for bonus year 2026, net of steps taken to offset it.

Humana added about 1,208,000 individual Medicare Advantage members in the first nine months of the year, a 23% increase, and said that growth is tracking its full-year expectation of about 25%, according to the prepared remarks.

What was said about 2027

Mellet said on the call, in the transcript published by The Motley Fool3, that "our #1 priority in AEP was to price for margin," referring to the annual enrollment period. She said the company significantly improved its product position for 2027.

The sharpest increase is in drug costs. Humana expects its Part D costs to rise 14% to 15% next year, driven by what Mellet called the health technology pipeline, meaning new high-cost drugs. She said that trend was priced into the bids for both Medicare Advantage plans with drug coverage and stand-alone Part D plans.

Rechtin said the company still expects its membership to be up in 2027, but that it is too early to put a number on it and that growth will not look like last year's. Mellet pointed to the number of plan exits across most of the major insurers as part of the backdrop.

The company's stated goal is a pre-tax margin of at least 3% on individual Medicare Advantage in 2028, and the prepared remarks say the approach to 2027 bids should drive meaningful progress toward it. Humana also said its Medicare Advantage Star Ratings for bonus year 2028, which feed into quality bonus payments for 2028, are industry leading.

What comes next

Open enrollment for 2027 Medicare Advantage and Part D plans ends December 7, and coverage under any new plan starts January 1, according to Medicare. Humana said it would not estimate 2027 membership until the enrollment period is further along. The figures to watch are the insurer's fourth-quarter benefit ratio, which it expects to be just above 95.5%, and whether the 8% to 9% medical cost assumption and the 14% to 15% Part D assumption hold once 2027 claims start arriving.

  • 01

    Lilly's obesity drugs go on sale through Hims & Hers.

    Zepbound, the injectable, starts at $299 a month and Foundayo, Lilly's daily pill, at $149 a month for self-pay patients, the same cash prices Lilly offers any patient, according to the companies' announcement on Friday. Hims & Hers has committed not to sell compounded copies of Lilly's drugs.

    Hims & Hers

  • 02

    Most brand-generic patent settlements now delay the generic

    Of 2,405 settlements reported to the Federal Trade Commission for fiscal 2004 through 2021, 86% restricted when the generic could launch, a share that rose from 36% in 2004 to 95% in 2021, a Harvard team reported in JAMA Health Forum on Friday.

    JAMA Health Forum

  • 03

    KFF reruns its 340B math on the final rule

    With Medicare paying hospitals average sales price minus 28% for 340B drugs from January 1, 2027, KFF estimates safety-net hospitals lose 5.2% of outpatient revenue while for-profit hospitals gain 6.8%, because the cut is offset by a 7.5% increase in payments for non-drug outpatient services.

    KFF

  • 04

    Four states sue over the Medicaid work requirement

    Oregon, joined by Minnesota, New Mexico and Washington, filed suit in federal court in Oregon on Thursday challenging the constitutionality of the work requirement that takes effect January 1, 2027, STAT reported. Oregon's Department of Justice says the rule would require more than half a million Oregonians to file regular paperwork to keep coverage.

    STAT, Oregon DOJ

Every figure in this story was checked against these sources on Saturday, November 7, 2026.

  1. 01Humana Inc., "Humana reports third quarter 2026 financial results; raises full year 2026 adjusted EPS guidance" (Form 8-K, Exhibit 99.1), November 6, 2026sec.gov
  2. 02Humana Inc., "Third quarter 2026 posted prepared remarks" (Form 8-K exhibit), November 6, 2026sec.gov
  3. 03The Motley Fool, "Humana (HUM) Q3 2026 earnings call transcript", November 6, 2026fool.com
  4. 04Reuters (via Yahoo Finance), "Humana raises full-year profit forecast", November 6, 2026finance.yahoo.com
  5. 05Medicare.gov, "Joining a plan" (Open Enrollment Period dates), accessed November 7, 2026medicare.gov
  6. 06Hims & Hers Health, "Lilly and Hims & Hers expand access to FDA-approved Lilly medicines", November 6, 2026investors.hims.com
  7. 07JAMA Health Forum, "Brand-generic patent settlements reported to the US Federal Trade Commission" (Daval, Egilman, Kesselheim), November 6, 2026jamanetwork.com
  8. 08KFF, "Medicare's cut to 340B drug payments would hit safety-net hospitals while benefiting for-profit hospitals" (updated for the final rule), November 6, 2026kff.org
  9. 09STAT, "States sue Trump administration to delay Medicaid work requirements", November 6, 2026statnews.com
  10. 10Oregon Department of Justice, "Federal litigation tracker: Medicaid work requirements (Oregon v. Oz, D. Or.)", filed November 5, 2026doj.state.or.us
  11. PhotoA Humana office tower in Louisville, Ky., where the insurer is based. Photo: Angry Aspie, via Wikimedia Commons (CC BY 3.0).commons.wikimedia.org
  1. The market

    Maryland finalizes the first state payment limits on a drug, for Ozempic and Jardiance

    Starting in January, state and local government health plans in Maryland can cap what they pay for the two drugs, and a 2025 law lets the board extend the limits to private insurance from 2028.

    3 min read

  2. The market

    Jefferson Health loses $81 million in a quarter as it presses insurers for higher rates

    Philadelphia's largest health system is using weak results to argue for higher commercial rates, six weeks before its contracts with three Blue Cross insurers expire.

    2 min read

  3. The market

    CVS says GLP-1 drugs would pay for themselves at about $350 a month

    CVS Health's own claims study finds that weight-loss and diabetes drugs cut hospital use but still raise what employers and plans spend per member, and it names the net price at which that would stop.

    3 min read

  4. The market

    Surgery Partners rejects a $28 bid, takes $25 a share from Bon Secours Mercy's HealthSpan

    The surgery center chain chose a hospital system's raised offer over a higher cash bid, reported to be UnitedHealth's, because the board judged the bigger number less likely to close.

    3 min read